{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089579","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.790494+00:00","generated_at":"2026-06-11T16:59:48.315946+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"low","headline":"Sagimet posts updated investor presentation on NASH, acne, cancer pipeline","bullets":["Company furnished investor slide deck dated August 10, 2023; no financial results disclosed.","Presentation focuses on novel therapies targeting metabolic dysfunction for NASH, acne, and cancer.","No quantitative updates (e.g., clinical data, revenue, guidance) provided in filing or exhibit."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089579","json":"https://secwatch.observer/filing/0001104659-23-089579.json","markdown":"https://secwatch.observer/filing/0001104659-23-089579.md","text":"https://secwatch.observer/filing/0001104659-23-089579.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923089579/0001104659-23-089579-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923089579/tm2323360d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T16:59:48.315946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}